Precision BioSciences’ (DTIL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $60.00 target price on the stock.

Separately, BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research report on Friday, January 10th.

Precision BioSciences Trading Up 9.7 %

Shares of DTIL opened at $5.65 on Wednesday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The stock has a market cap of $43.34 million, a PE ratio of 94.18 and a beta of 1.51. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $19.43. The stock has a 50 day simple moving average of $4.88 and a 200-day simple moving average of $7.34.

Insider Buying and Selling at Precision BioSciences

In related news, CEO Michael Amoroso sold 36,838 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the transaction, the chief executive officer now directly owns 107,087 shares in the company, valued at $500,096.29. This represents a 25.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider J. Jefferson Smith sold 10,287 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the sale, the insider now owns 87,440 shares of the company’s stock, valued at $418,837.60. This represents a 10.53 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 8,734 shares of company stock worth $39,946. 4.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC grew its position in Precision BioSciences by 10.9% in the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after purchasing an additional 68,943 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Precision BioSciences by 40.7% in the third quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock valued at $591,000 after purchasing an additional 19,088 shares during the period. Moloney Securities Asset Management LLC lifted its position in Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock worth $335,000 after acquiring an additional 56,100 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in Precision BioSciences in the 4th quarter valued at $48,000. Finally, Samalin Investment Counsel LLC bought a new stake in shares of Precision BioSciences in the fourth quarter valued at about $59,000. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.